Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review.

ABSTRACT: The implementation of immune checkpoint-inhibitors (CPI) has significantly improved the prognosis of a subgroup of patients with urothelial bladder cancer (BC). Still, the majority of patients will progress or experience a recurrence on CPI monotherapy. The next generation of clinical trials is now testing combination therapy with CPI and other agents that target different oncogenic mechanisms in an effort to improve efficacy. The beneficial toxicity profile of CPI but also the approval of CPI combinations in other cancer sites justifies their investigation also in BC. Here we report on clinical trials in muscle-invasive, locally advanced and metastatic BC combining CPI with other therapies, with a focus on the latest results presented at ASCO GU 2020, ASCO 2020 and ESMO 2019 as well as Ph

SUBMITTER: Schulz GB 

PROVIDER: S-EPMC8575593 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature